Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil and Durvalumab in Advanced Women's Cancers
NCT02725489Phase 2Completed
- Sponsor
- Sarah Cannon Research Institute
- Start
- Jun 2016
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of gemogenovatucel-T in breast cancer, ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), uterine cancer, sponsored by Sarah Cannon Research Institute. Started Jun 2016; status: completed.
02
Drugs
gemogenovatucel-T
03
Conditions
breast cancerovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)uterine cancer
Beyond the preview
Go deeper on NCT02725489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725489.